image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 102.02
0.492 %
$ 2.29 B
Market Cap
56.05
P/E
1. INTRINSIC VALUE

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin.[ Read More ]

The intrinsic value of one LMAT stock under the base case scenario is HIDDEN Compared to the current market price of 102 USD, LeMaitre Vascular, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart LMAT

image
FINANCIALS
193 M REVENUE
19.69%
37.1 M OPERATING INCOME
75.21%
30.1 M NET INCOME
45.89%
36.8 M OPERATING CASH FLOW
44.81%
-24.7 M INVESTING CASH FLOW
-138.31%
-7.13 M FINANCING CASH FLOW
22.77%
54.8 M REVENUE
-1.84%
13.1 M OPERATING INCOME
-8.57%
11.1 M NET INCOME
-5.79%
14.2 M OPERATING CASH FLOW
48.01%
-12.9 M INVESTING CASH FLOW
-16.91%
-3.15 M FINANCING CASH FLOW
-9.69%
Balance Sheet Decomposition LeMaitre Vascular, Inc.
image
Current Assets 195 M
Cash & Short-Term Investments 105 M
Receivables 25.1 M
Other Current Assets 64.5 M
Non-Current Assets 152 M
Long-Term Investments 0
PP&E 39.8 M
Other Non-Current Assets 112 M
Current Liabilities 29.9 M
Accounts Payable 3.73 M
Short-Term Debt 4.94 M
Other Current Liabilities 21.2 M
Non-Current Liabilities 19 M
Long-Term Debt 16.6 M
Other Non-Current Liabilities 2.38 M
EFFICIENCY
Earnings Waterfall LeMaitre Vascular, Inc.
image
Revenue 193 M
Cost Of Revenue 66.4 M
Gross Profit 127 M
Operating Expenses 90.3 M
Operating Income 37.1 M
Other Expenses 6.98 M
Net Income 30.1 M
RATIOS
65.66% GROSS MARGIN
65.66%
19.17% OPERATING MARGIN
19.17%
15.56% NET MARGIN
15.56%
10.11% ROE
10.11%
8.68% ROA
8.68%
9.42% ROIC
9.42%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis LeMaitre Vascular, Inc.
image
Net Income 30.1 M
Depreciation & Amortization 9.52 M
Capital Expenditures -7.26 M
Stock-Based Compensation 5.32 M
Change in Working Capital -11.3 M
Others -13.6 M
Free Cash Flow 29.5 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets LeMaitre Vascular, Inc.
image
Wall Street analysts predict an average 1-year price target for LMAT of $90.3 , with forecasts ranging from a low of $75 to a high of $100 .
LMAT Lowest Price Target Wall Street Target
75 USD -26.49%
LMAT Average Price Target Wall Street Target
90.3 USD -11.46%
LMAT Highest Price Target Wall Street Target
100 USD -1.98%
4. DIVIDEND ANALYSIS
0.17% DIVIDEND YIELD
0.16 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership LeMaitre Vascular, Inc.
image
Sold
0-3 MONTHS
152 K USD 1
3-6 MONTHS
9.12 M USD 4
6-9 MONTHS
26.3 M USD 6
9-12 MONTHS
4 M USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
4 days ago
Nov 13, 2024
Sell 111 K USD
SHADAN MARTHA
Director
- 1070
103.374 USD
4 days ago
Nov 13, 2024
Sell 40.9 K USD
SHADAN MARTHA
Director
- 396
103.3765 USD
3 months ago
Aug 13, 2024
Sell 251 K USD
Roberts David B
President and Director
- 3063
82.07 USD
3 months ago
Aug 05, 2024
Sell 14.9 K USD
Kamke Trent G
Senior V. P., Operations
- 182
81.82 USD
4 months ago
Jul 16, 2024
Sell 4.97 M USD
LeMaitre George W
Chairman and CEO
- 57372
86.6937 USD
4 months ago
Jul 12, 2024
Sell 1.12 M USD
LeMaitre George W
Chairman and CEO
- 12976
86.07 USD
4 months ago
Jul 15, 2024
Sell 2.33 M USD
LeMaitre George W
Chairman and CEO
- 27030
86.2711 USD
6 months ago
May 16, 2024
Sell 429 K USD
Ross Bridget A
Director
- 5500
77.99 USD
6 months ago
May 13, 2024
Sell 2.74 M USD
LeMaitre George W
Chairman and CEO
- 35826
76.4162 USD
6 months ago
May 14, 2024
Sell 3.15 M USD
LeMaitre George W
Chairman and CEO
- 40968
76.8007 USD
6 months ago
May 06, 2024
Sell 1.77 M USD
LeMaitre George W
Chairman and CEO
- 23206
76.1211 USD
6 months ago
May 06, 2024
Sell 2.22 M USD
LeMaitre George W
Chairman and CEO
- 29500
75.2308 USD
6 months ago
May 06, 2024
Sell 1.23 M USD
LeMaitre George W
Chairman and CEO
- 16200
75.9406 USD
6 months ago
May 07, 2024
Sell 1.96 M USD
LeMaitre George W
Chairman and CEO
- 26044
75.2389 USD
6 months ago
May 07, 2024
Sell 1.54 M USD
LeMaitre George W
Chairman and CEO
- 20256
75.856 USD
6 months ago
May 08, 2024
Sell 602 K USD
LeMaitre George W
Chairman and CEO
- 8000
75.3034 USD
6 months ago
May 06, 2024
Sell 380 K USD
Roberts David B
President and Director
- 5025
75.62 USD
8 months ago
Mar 08, 2024
Sell 234 K USD
Kamke Trent G
Senior V. P., Operations
- 3442
68.024 USD
8 months ago
Mar 08, 2024
Sell 75.5 K USD
Kamke Trent G
Senior V. P., Operations
- 1100
68.678 USD
8 months ago
Mar 07, 2024
Sell 518 K USD
Roush John A
Director
- 7500
69 USD
8 months ago
Mar 05, 2024
Sell 345 K USD
Jasinski Lawrence J
Director
- 5110
67.5 USD
8 months ago
Feb 29, 2024
Sell 88.9 K USD
LeMaitre George W
Chairman and CEO
- 1300
68.37 USD
8 months ago
Feb 29, 2024
Sell 1.43 M USD
LeMaitre George W
Chairman and CEO
- 20575
69.69 USD
8 months ago
Feb 29, 2024
Sell 420 K USD
LeMaitre George W
Chairman and CEO
- 5984
70.14 USD
8 months ago
Mar 01, 2024
Sell 1.07 M USD
LeMaitre George W
Chairman and CEO
- 15869
67.51 USD
8 months ago
Mar 01, 2024
Sell 1.37 M USD
LeMaitre George W
Chairman and CEO
- 20200
68.04 USD
8 months ago
Mar 01, 2024
Sell 66.2 K USD
LeMaitre George W
Chairman and CEO
- 950
69.64 USD
8 months ago
Mar 04, 2024
Sell 2.23 M USD
LeMaitre George W
Chairman and CEO
- 32800
67.95 USD
8 months ago
Mar 04, 2024
Sell 261 K USD
LeMaitre George W
Chairman and CEO
- 3800
68.68 USD
8 months ago
Feb 29, 2024
Sell 136 K USD
Pellegrino Joseph P JR
Chief Financial Officer
- 1979
68.56 USD
8 months ago
Feb 29, 2024
Sell 1.98 M USD
Pellegrino Joseph P JR
Chief Financial Officer
- 28461
69.724 USD
8 months ago
Feb 29, 2024
Sell 439 K USD
Pellegrino Joseph P JR
Chief Financial Officer
- 6250
70.27 USD
8 months ago
Feb 29, 2024
Sell 19.7 K USD
Pellegrino Joseph P JR
Chief Financial Officer
- 277
71.19 USD
11 months ago
Dec 11, 2023
Sell 1.2 M USD
LeMaitre George W
Chairman and CEO
- 22088
54.41 USD
11 months ago
Dec 11, 2023
Sell 11 K USD
LeMaitre George W
Chairman and CEO
- 200
54.99 USD
11 months ago
Dec 07, 2023
Sell 763 K USD
LeMaitre George W
Chairman and CEO
- 14000
54.5 USD
11 months ago
Dec 07, 2023
Sell 598 K USD
LeMaitre George W
Chairman and CEO
- 10869
54.99 USD
11 months ago
Dec 08, 2023
Sell 1.42 M USD
LeMaitre George W
Chairman and CEO
- 26126
54.5273 USD
1 year ago
Jun 02, 2023
Sell 321 K USD
Ross Bridget A
Director
- 5000
64.24 USD
1 year ago
May 19, 2023
Sell 385 K USD
LeMaitre George W
Chairman and CEO
- 6150
62.54 USD
1 year ago
May 19, 2023
Sell 60.2 K USD
LeMaitre George W
Chairman and CEO
- 948
63.49 USD
1 year ago
May 17, 2023
Sell 137 K USD
LeMaitre George W
Chairman and CEO
- 2143
64.05 USD
1 year ago
May 17, 2023
Sell 2.14 K USD
LeMaitre George W
Chairman and CEO
- 33
64.82 USD
1 year ago
May 18, 2023
Sell 1.12 M USD
LeMaitre George W
Chairman and CEO
- 17660
63.26 USD
1 year ago
May 18, 2023
Sell 16 K USD
LeMaitre George W
Chairman and CEO
- 250
64.02 USD
1 year ago
May 09, 2023
Sell 493 K USD
Roush John A
Director
- 7500
65.739 USD
1 year ago
May 09, 2023
Sell 241 K USD
Jasinski Lawrence J
Director
- 3648
66 USD
1 year ago
May 04, 2023
Sell 617 K USD
Roberts David B
President and Director
- 9664
63.8423 USD
1 year ago
May 04, 2023
Sell 944 K USD
Roberts David B
President and Director
- 14961
63.0958 USD
1 year ago
May 04, 2023
Sell 103 K USD
Roberts David B
President and Director
- 1665
62.1571 USD
1 year ago
May 04, 2023
Sell 253 K USD
Roberts David B
President and Director
- 3899
64.9736 USD
1 year ago
May 04, 2023
Sell 302 K USD
Roberts David B
President and Director
- 4800
62.9236 USD
1 year ago
May 03, 2023
Sell 6.02 M USD
LeMaitre George W
Chairman and CEO
- 94900
63.4796 USD
1 year ago
May 04, 2023
Sell 326 K USD
LeMaitre George W
Chairman and CEO
- 5100
63.9795 USD
1 year ago
Mar 03, 2023
Sell 327 K USD
Kamke Trent G
Senior V. P., Operations
- 6414
50.9416 USD
1 year ago
Mar 02, 2023
Sell 9.6 K USD
Jasinski Lawrence J
Director
- 192
50 USD
1 year ago
Feb 27, 2023
Sell 46.4 K USD
Roberts David B
President and Director
- 905
51.31 USD
1 year ago
Feb 27, 2023
Sell 85.5 K USD
Roberts David B
President and Director
- 1700
50.27 USD
1 year ago
Feb 27, 2023
Sell 568 K USD
Roberts David B
President and Director
- 11503
49.39 USD
1 year ago
Feb 27, 2023
Sell 345 K USD
Ross Bridget A
Director
- 7000
49.27 USD
7. News
LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story LeMaitre continues to expand in the peripheral vascular disease market, with recent revenue gains driven by premium pricing and international growth. Its strong dividend growth of 14.3% this year and double-digit CAGR over the past five years are particularly appealing. With a high-margin, low-competition niche and accelerating geographic expansion, LeMaitre remains well-positioned for sustained growth. seekingalpha.com - 1 week ago
LeMaitre to Participate at Upcoming Investor Conferences in November BURLINGTON, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in three upcoming investor conferences in November. globenewswire.com - 2 weeks ago
LeMaitre Vascular, Inc. (LMAT) Q3 2024 Earnings Call Transcript LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q3 2024 Earnings Conference Call October 33, 2024 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chief Executive Officer Dave Roberts - President Conference Call Participants Suraj Kalia - Oppenheimer Rick Wise - Stifel Brett Fishbin - KeyBanc Jason Wittes - Roth Danny Stauder - Citizens JMP Michael Petusky - Barrington Research Frank Takkinen - Lake Street Capital Markets Jim Sidoti - Sidoti & Company Ross Osborn - Cantor Fritzgerald Operator Welcome to the LeMaitre Vascular Q3 2024 Financial Results Conference Call. seekingalpha.com - 2 weeks ago
LeMaitre Vascular (LMAT) Surpasses Q3 Earnings and Revenue Estimates LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.33 per share a year ago. zacks.com - 2 weeks ago
LeMaitre Q3 2024 Financial Results BURLINGTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q3 2024 results, announced a $0.16/share quarterly dividend, and provided guidance. globenewswire.com - 2 weeks ago
BAX or LMAT: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Products sector might want to consider either Baxter International (BAX) or LeMaitre Vascular (LMAT). But which of these two companies is the best option for those looking for undervalued stocks? zacks.com - 4 weeks ago
LeMaitre Will Announce Third Quarter 2024 Earnings Results October 31, 2024 BURLINGTON, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2024 financial results on Thursday, October 31, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. globenewswire.com - 1 month ago
BAX vs. LMAT: Which Stock Is the Better Value Option? Investors looking for stocks in the Medical - Products sector might want to consider either Baxter International (BAX) or LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now? zacks.com - 1 month ago
All You Need to Know About LeMaitre (LMAT) Rating Upgrade to Strong Buy LeMaitre (LMAT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 1 month ago
LeMaitre to Participate at Upcoming Investor Conferences in September BURLINGTON, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in three upcoming investor conferences in September. globenewswire.com - 2 months ago
LeMaitre (LMAT) Upgraded to Strong Buy: Here's Why LeMaitre (LMAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). zacks.com - 3 months ago
Best Momentum Stock to Buy for August 6th HWKN, PPC and LMAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 6, 2024. zacks.com - 3 months ago
8. Profile Summary

LeMaitre Vascular, Inc. LMAT

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 2.29 B
Dividend Yield 0.17%
Description LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Contact 63 Second Avenue, Burlington, MA, 01803 https://www.lemaitre.com
IPO Date Oct. 19, 2006
Employees 614
Officers Mr. David B. Roberts President & Director Dr. George D. LeMaitre Founder and Chairman of Scientific Advisory Board Mr. Jonathan W. Ngau Senior Vice President of Information Technology Mr. Trent G. Kamke Senior Vice President of Operations Ms. Kimberly L. Cieslak Vice President of Marketing Mr. Maik D. Helmers Senior Vice President of Sales – Central Europe Mr. Daniel J. Mumford Senior Director of Human Resources Mr. Ryan H. Connelly Senior Vice President of Advanced Manufacturing Engineering Mr. Joseph P. Pellegrino Jr. Chief Financial Officer, Secretary & Director Mr. George W. LeMaitre Chairman & Chief Executive Officer